4.7 Article

Parental Permission for Pilot Newborn Screening Research: Guidelines From the NBSTRN

Journal

PEDIATRICS
Volume 133, Issue 2, Pages E410-E417

Publisher

AMER ACAD PEDIATRICS
DOI: 10.1542/peds.2013-2271

Keywords

newborn screening; research; research ethics; informed consent; parental permission

Categories

Funding

  1. Eunice Kennedy Shriver National Institute of Child Health and Human Development [HHSN275200800001C]
  2. National Institutes of Health [R01HD069045]
  3. National Institutes of Health (NIH)

Ask authors/readers for more resources

There is broad recognition of the need for population-based research to assess the safety and efficacy of newborn screening (NBS) for conditions that are not on current panels. However, prospective population-based research poses significant ethical, regulatory, and logistical challenges. In the context of NBS, there have been a variety of approaches that address parental decision-making in pilot studies of new screening tests or conditions. This article presents an ethical and legal analysis of the role of parental permission by the Bioethics and Legal Work Group of the Newborn Screening Translational Research Network created under a contract from the National Institute of Child Health and Human Development to the American College of Medical Genetics and Genomics. Circumstances are outlined in which a waiver of documentation of permission or a waiver of permission may be ethically and legally appropriate in the NBS context. These guidelines do not constitute American Academy of Pediatrics policy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Genetics & Heredity

Detection of SMN1 to SMN2 gene conversion events and partial SMN1 gene deletions using array digital PCR

Deborah L. Stabley, Jennifer Holbrook, Mena Scavina, Thomas O. Crawford, Kathryn J. Swoboda, Katherine M. Robbins, Matthew E. R. Butchbach

Summary: Proximal spinal muscular atrophy (SMA) is an early-onset motor neuron disease caused by deletion or disabling mutations of survival motor neuron 1 (SMN1) and affected by the copy number of paralog SMN2. Array digital PCR (dPCR) can accurately and reliably measure SMN1 and SMN2 copy numbers and detect gene conversion events and partial deletions of SMN1. In SMA, higher SMN2 copy numbers are associated with milder disease severity.

NEUROGENETICS (2021)

Article Clinical Neurology

Increased systemic HSP70B levels in spinal muscular atrophy infants

Eric J. Eichelberger, Christiano R. R. Alves, Ren Zhang, Marco Petrillo, Patrick Cullen, Wildon Farwell, Jessica A. Hurt, John F. Staropoli, Kathryn J. Swoboda

Summary: This study identified HSPA7/HSP70B as a potential novel biomarker for tracking SMA progression, with changes in levels correlating with circulating neurofilament levels in SMA newborns and infants. Further research will determine the response of HSP70B levels to molecular therapies.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Article Genetics & Heredity

Rare presentation of FDX2-related disorder and untargeted global metabolomics findings

Anjali Aggarwal, Nishitha R. Pillai, Charles J. Billington, Lynn Schema, Susan A. Berry

Summary: This case describes a 20-year-old male with a history of myopathy, multiple episodes of rhabdomyolysis, and lactic acidosis, attributed to a likely pathogenic variant in the FDX2 gene. The patient is the third reported case of FDX2-related rhabdomyolysis, with unique metabolic features observed during episodes of metabolic decompensation.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2022)

Article Endocrinology & Metabolism

Methionine synthase deficiency: Variable clinical presentation and benefit of early diagnosis and treatment

Kimberly A. Kripps, Leighann Sremba, Austin A. Larson, Johan L. K. Van Hove, Hoanh Nguyen, Erica L. Wright, David M. Mirsky, David Watkins, David S. Rosenblatt, David Ketteridge, Susan A. Berry, Shawn E. McCandless, Peter R. Baker

Summary: Methionine synthase deficiency (cblG complementation group) is a rare inborn error of metabolism that can present with a variety of clinical symptoms. Treatment with hydroxocobalamin, betaine, folinic acid, and methionine supplementation has shown improvement in biochemical profiles of affected patients, with more favorable outcomes observed in those treated early in life. Further research is needed to determine the long-term efficacy of treatment for cblG.

JOURNAL OF INHERITED METABOLIC DISEASE (2022)

Review Communication

Healthcare team communication training in the United States: A scoping review

Julia R. Hathaway, Beth A. Tarini, Sushmita Banerjee, Caroline O. Smolkin, Jessica A. Koos, Susmita Pati

Summary: This literature review aimed to identify interventions designed to improve healthcare team communication in the United States. The study found a variety of interventions, including didactic lectures, simulation, quality improvement, etc., but their effectiveness was inconsistent. Interventions conducted at academic medical centers had better outcomes and utilized statistical analysis for evaluation.

HEALTH COMMUNICATION (2023)

Article Pediatrics

Pediatrician Adherence to Guidelines for Diagnosis and Management of High Blood Pressure

Corinna J. Rea, Tammy M. Brady, David G. Bundy, Moonseong Heo, Elissa Faro, Kimberly Giuliano, Beatrice Goilav, Peterkaye Kelly, Kelly Orringer, Beth A. Tarini, Katherine Twombley, Michael L. Rinke

Summary: This study found that pediatrician adherence to the 2017 American Academy of Pediatrics' clinical practice guideline for high blood pressure was low. Only a small percentage of patients received appropriate blood pressure measurements and related counseling and follow-up, highlighting the need for improvement in the recognition and management of childhood hypertension.

JOURNAL OF PEDIATRICS (2022)

Article Genetics & Heredity

Using Long-Term Follow-Up Data to Classify Genetic Variants in Newborn Screened Conditions

Kevin Wilhelm, Mathew J. Edick, Susan A. Berry, Michael Hartnett, Amy Brower

Summary: With the increasing availability of publicly available sequencing data, it is crucial for healthcare professionals to understand the impact of genetic variation on diagnosis and patient health outcomes. By analyzing longitudinal health information from newborn screening, unreported genetic variants can be discovered, and the accompanying clinical information can provide insights into the relationship between genotype and phenotype.

FRONTIERS IN GENETICS (2022)

Article Biochemistry & Molecular Biology

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, Kayoko Saito, Jerry R. Mendell, Laurent Servais, Hugh J. McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie A. Parsons, Perry B. Shieh, Sarah Kavanagh, Melissa Wigderson, Sitra Tauscher-Wisniewski, Bryan E. McGill, Thomas A. Macek

Summary: Onasemnogene abeparvovec was effective and well tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.

NATURE MEDICINE (2022)

Article Biochemistry & Molecular Biology

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, Kayoko Saito, Jerry R. Mendell, Laurent Servais, Hugh J. McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie A. Parsons, Perry B. Shieh, Sarah Kavanagh, Sitra Tauscher-Wisniewski, Bryan E. McGill, Thomas A. Macek

Summary: SPR1NT (NCT03505099) is a Phase III study investigating the efficacy and safety of onasemnogene abeparvovec in presymptomatic children with biallelic SMN1 mutations. The results showed that all 14 infants enrolled in the study were able to sit independently for at least 30 seconds within 18 months and none required permanent ventilation. The treatment was well tolerated and effective for children expected to develop SMA type 1.

NATURE MEDICINE (2022)

Article Genetics & Heredity

Population-Based Screening of Newborns: Findings From the NBS Expansion Study (Part One)

Amy Brower, Kee Chan, Marc Williams, Susan Berry, Robert Currier, Piero Rinaldo, Michele Caggana, Amy Gaviglio, William Wilcox, Robert Steiner, Ingrid A. Holm, Jennifer Taylor, Joseph J. Orsini, Luca Brunelli, Joanne Adelberg, Olaf Bodamer, Sarah Viall, Curt Scharfe, Melissa Wasserstein, Jin Y. Chen, Maria Escolar, Aaron Goldenberg, Kathryn Swoboda, Can Ficicioglu, Dieter Matern, Rachel Lee, Michael Watson

Summary: Each year, a significant number of newborns are identified with conditions through population-based newborn screening (NBS), and advancements in genomic technologies hold promise to expand NBS. However, the expansion of NBS in the United States is slow and occurs condition by condition and state by state. The Newborn Screening Translational Research Network (NBSTRN) conducted the NBS Expansion Study to identify challenges and propose improvements, and found that the capacity to expand NBS varies across the US with an average adoption time of 9.5 years for a new condition. Four factors delaying and complicating NBS expansion were identified.

FRONTIERS IN GENETICS (2022)

Article Genetics & Heredity

Outcomes and genotype correlations in patients with mitochondrial trifunctional protein or isolated long chain 3-hydroxyacyl-CoA dehydrogenase deficiency enrolled in the IBEM-IS database

Chelsey Chaehee Lim, Jerry Vockley, Otobo Ujah, Russell S. Kirby, Mathew J. Edick, Susan A. Berry, Georgianne L. Arnold

Summary: This study collected data from 45 cases of mitochondrial trifunctional protein deficiency (TFPD) or isolated long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) to analyze the natural history of these conditions. The study found that different genotypes lead to different symptom profiles, highlighting the importance of genotypic confirmation for diagnosis and treatment.

MOLECULAR GENETICS AND METABOLISM REPORTS (2022)

Article Genetics & Heredity

Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors

Martin Kharrazi, Charlene Sacramento, Anne Marie Comeau, Jaime E. Hale, Michele Caggana, Denise M. Kay, Rachel Lee, Brendan Reilly, John D. Thompson, Samya Z. Nasr, Mary Kleyn, Gary Hoffman, Mei W. Baker, Colleen Clarke, Cheryl L. Harris, M. Christine Dorley, Hilary Fryman, Ankit Sutaria, Amy Hietala, Holly Winslow, Holly Richards, Bradford L. Therrell

Summary: This survey aimed to identify factors associated with missed cystic fibrosis cases due to low immunoreactive trypsinogen (IRT) levels below program cutoffs. Factors such as race, IRT cutoff values, genotypes, and birth and feeding factors were found to be associated with missed CF cases. Lowering IRT cutoff values and addressing hospital and laboratory factors may help reduce missed CF cases.

INTERNATIONAL JOURNAL OF NEONATAL SCREENING (2022)

Article Clinical Neurology

Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study

Thomas J. Crawford, Kathryn C. Swoboda, Darryl De Vivo, Enrico Bertini, Wuh-Liang S. Hwu, Richard Finkel, Janbernd L. Kirschner, Nancy Kuntz, Aledie Navas A. Nazario, Julie Parsons, Astrid M. Pechmann, M. Monique M. J. Ryan, Russell Butterfield, Haluk Topaloglu, Tawfeg A. Ben-Omran, Valeria Sansone, Yuh-Jyh Jong, Francy Shu, Cong Zhu, Stephanie R. Raynaud, Tiffany D. Lago, Angela Paradis, Richard Foster, Russell Chin, Zdenek Berger, NURTURE Study Grp

Summary: The NURTURE study provides evidence for the effectiveness and safety of early treatment with nusinersen in children with presymptomatic spinal muscular atrophy. The results demonstrate the durability of treatment effects and the potential for improved outcomes in motor function and survival.

MUSCLE & NERVE (2023)

Article Genetics & Heredity

Genomics and Newborn Screening: Perspectives of Public Health Programs

Aaron J. Goldenberg, Roselle Ponsaran, Amy Gaviglio, Dalton Simancek, Beth A. Tarini

Summary: This study examines the benefits and challenges of using genomics in Newborn Screening Programs from the perspectives of State program officials. The integration of genomics can improve screening modalities and support diagnostic procedures, but it also faces challenges such as high costs, education needs, and potential negative psychosocial impact.

INTERNATIONAL JOURNAL OF NEONATAL SCREENING (2022)

Article Genetics & Heredity

Successful Implementation of Expanded Newborn Screening in the Philippines Using Tandem Mass Spectrometry

Carmencita D. Padilla, Bradford L. Therrell Jr, Maria Melanie Liberty B. Alcausin, Mary Anne D. Chiong, Mary Ann R. Abacan, Ma Elouisa L. Reyes, Charity M. Jomento, Maria Truda T. Dizon-Escoreal, Margarita Aziza E. Canlas, Michelle E. Abadingo, J. Edgar Winston C. Posecion, Conchita G. Abarquez, Alma P. Andal, Anna Lea G. Elizaga, Bernadette C. Halili-Mendoza, Maria Paz Virginia K. Otayza, David S. Millington

Summary: Newborn bloodspot screening began as a research project in the Philippines in 1996 and was mandated by law in 2004. As screening technology and medical knowledge have advanced, NBS programs in countries with developed economies have also expanded, while low- and middle-income countries face challenges in selecting conditions for screening and implementing sustainable programs.

INTERNATIONAL JOURNAL OF NEONATAL SCREENING (2022)

No Data Available